494
Participants
Start Date
October 31, 2018
Primary Completion Date
March 17, 2020
Study Completion Date
March 17, 2020
Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%
Once daily for 4 weeks (28 days)
Enstilar® foam (LEO Pharma Inc.)
Once daily for 4 weeks (28 days)
Placebo of Calcipotriene/ betamethasone dipropionate topical foam
Once daily for 4 weeks (28 days)
Investigational Site 28, New York
Investigational Site 6, Norfolk
Investigational Site 4, High Point
Investigational Site 24, Wilmington
Investigational Site 13, Greenville
Investigational Site 27, Coral Gables
Investigational Site 1, Miami
Investigational Site 29, Clearwater
Investigational Site 26, Pinellas Park
Investigational site 31, Murfreesboro
Investigational Site 25, Nashville
Investigational Site 7, Knoxville
Investigational Site 16, Louisville
Investigational Site 8, Beachwood
Investigational Site 2, Cincinnati
Investigational Site 10, New Albany
Investigational Site 21, Saint Joseph
Investigational Site 3, Overland Park
Investigational Site 30, Webster
Investigational Site 11, San Antonio
Investigational Site 14, San Antonio
Investigational Site 5, Austin
Investigational Site 12, Henderson
Investigational Site 22, Santa Monica
Investigational Site 20, Encinitas
Investigational Site 19, San Diego
Investigational Site 15, San Diego
Investigational Site 23, San Diego
Investigational Site 17, Santa Ana
Investigational Site 18, Fountain Valley
Lead Sponsor
Glenmark Pharmaceuticals Ltd. India
INDUSTRY